Novo Nordisk ADR (NYSE: NVO) started the day on Wednesday, with a price increase of 2.57% at $105.27, before settling in for the price of $102.63 at the close. Taking a more long-term approach, NVO posted a 52-week range of $94.73-$148.15.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 14.25% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 16.48%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 21.16%. This publicly-traded company’s shares outstanding now amounts to $3.38 billion, simultaneously with a float of $3.34 billion. The organization now has a market capitalization sitting at $351.44 billion. At the time of writing, stock’s 50-day Moving Average stood at $116.79, while the 200-day Moving Average is $127.98.
Novo Nordisk ADR (NVO) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – General Industry. Novo Nordisk ADR’s current insider ownership accounts for 0.02%, in contrast to 10.03% institutional ownership.
Novo Nordisk ADR (NVO) Earnings and Revenue Records
Novo Nordisk ADR’s EPS increase for this current 12-month fiscal period is 21.16% and is forecasted to reach 4.09 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.00% through the next 5 years, which can be compared against the 16.48% growth it accomplished over the previous five years trading on the market.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
Let’s observe the current performance indicators for Novo Nordisk ADR (NVO). It’s Quick Ratio in the last reported quarter now stands at 0.75. The Stock has managed to achieve an average true range (ATR) of 2.73. Alongside those numbers, its PE Ratio stands at $34.14, and its Beta score is 0.41. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.94. Similarly, its price to free cash flow for trailing twelve months is now 31.01.
In the same vein, NVO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 3.08, a figure that is expected to reach 0.89 in the next quarter, and analysts are predicting that it will be 4.09 at the market close of one year from today.
Technical Analysis of Novo Nordisk ADR (NVO)
If we take a close look at the recent performances of Novo Nordisk ADR (NYSE: NVO), its last 5-days Average volume was 6.93 million that shows progress from its year to date volume of 4.5 million. During the previous 9 days, stock’s Stochastic %D was recorded 28.15% While, its Average True Range was 2.82.
Raw Stochastic average of Novo Nordisk ADR (NVO) in the period of the previous 100 days is set at 13.21%, which indicates a major fall in contrast to 43.01% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 33.95% that was lower than 34.98% volatility it exhibited in the past 100-days period.
